Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Positive results for CAPTIVATE: ibrutinib and venetoclax for CLL

Paolo Ghia • 14 Jun 2018
EHA 2018
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax
CAPTIVATE

Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, presented preliminary data from the Phase II CAPTIVATE trial (NCT02910583) at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. This trial combined ibrutinib and venetoclax in the frontline treatment of chronic lymphocytic leukemia (CLL), with the aim of yielding deeper responses than current standard therapies. Dr Ghia discusses the promising data from the trial, with 86% of patients reaching MRD negativity, and the treatment being as well tolerated as standard monotherapies.

More from Paolo Ghia

1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
2:20
Monoclonal B-cell lymphocytosis: at a crossroad between disease and senescence
Paolo Ghia • 8 Dec 2023
3:00
Five-year follow-up of the CAPTIVATE trial: ibrutinib retreatment in patients with CLL
Paolo Ghia • 8 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals